PRF Technologies Ltd.
For the period ended May 26, 2026. Filed May 26, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
May 26, 2026 · Filed May 26, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Study Design
Study Design
The preclinical study was conducted in a validated pig incisional pain model, with von Frey methodology, used extensively to evaluate post-operative analgesic therapies. Animals were randomized to receive a single administration of either PRF-110 or ZYNRELEF into the surgical wound bed prior to closure. Pain-related endpoints were assessed at multiple timepoints over a 72-hour post-operative period.
Analgesic activity was evaluated using standard measures of incisional pain in pigs, including behavioral and functional parameters, as well as stimulus-evoked responses. The active treatment arms were assessed for magnitude and duration of analgesic effect across early and late post-operative time windows.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.